Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **Ocumension Therapeutics**

歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

## DELAY IN DESPATCH OF CIRCULAR IN RELATION TO PROPOSED ADOPTION OF 2021 SHARE OPTION SCHEME, PROPOSED GRANT OF OPTIONS AND PROPOSED GRANT OF AWARDS UNDER 2021 SHARE AWARD SCHEME

Reference is made to the announcement (the "Announcement") of Ocumension Therapeutics (the "Company") dated July 2, 2021. Unless the context otherwise requires, terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, a circular (the "Circular") containing, among other things, details of the 2021 Share Option Scheme, the Proposed Grant of Options and the Proposed Grant of Awards to Directors under the 2021 Share Award Scheme, and other matters to be transacted at the EGM, together with the notice convening the EGM, was expected to be despatched to the Shareholders on or before August 6, 2021.

As additional time is required to prepare and finalize certain information to be included in the Circular, it is expected that the despatch date of the Circular will be postponed to a date falling on or before August 13, 2021.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, August 6, 2021

As at the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive Directors.